NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.18 +0.38 (+2.02 %) (As of 08/20/2018 04:00 PM ET)Previous Close$19.14Today's Range$19.14 - $19.5452-Week Range$16.65 - $50.57Volume2,286 shsAverage Volume205,845 shsMarket Capitalization$1.05 billionP/E Ratio-5.79Dividend YieldN/ABeta0.92 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. Receive DBVT News and Ratings via Email Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:DBVT CUSIPN/A Webwww.dbv-technologies.com Phone33-1-55-42-78-78 Debt Debt-to-Equity Ratio0.01 Current Ratio4.37 Quick Ratio4.37 Price-To-Earnings Trailing P/E Ratio-5.79 Forward P/E Ratio-5.09 P/E GrowthN/A Sales & Book Value Annual Sales$13.45 million Price / Sales81.34 Cash FlowN/A Price / CashN/A Book Value$2.94 per share Price / Book6.52 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees244 Outstanding Shares57,040,000Market Cap$1.05 billion DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions What is DBV TECHNOLOGIE/S's stock symbol? DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT." How were DBV TECHNOLOGIE/S's earnings last quarter? DBV TECHNOLOGIE/S (NASDAQ:DBVT) posted its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History. What price target have analysts set for DBVT? 9 brokers have issued 12 month target prices for DBV TECHNOLOGIE/S's shares. Their predictions range from $28.00 to $57.00. On average, they anticipate DBV TECHNOLOGIE/S's stock price to reach $42.5714 in the next twelve months. This suggests a possible upside of 121.5% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S. What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DBV TECHNOLOGIE/S. Who are some of DBV TECHNOLOGIE/S's key competitors? Some companies that are related to DBV TECHNOLOGIE/S include Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO) and Denali Therapeutics (DNLI). Who are DBV TECHNOLOGIE/S's key executives? DBV TECHNOLOGIE/S's management team includes the folowing people: Dr. Pierre-Henri Benhamou, Co-Founder, Chairman & CEO (Age 63)Mr. David Schilansky, Deputy CEO & Principal Financial Officer (Age 43)Mr. Bertrand Dupont, Co-Founder & CTO (Age 66)Mr. Charles Ruban, Chief Operating Officer (Age 46)Dr. Hugh A. Sampson, Chief Scientific Officer & Member of The Scientific Advisory Board (Age 69) Has DBV TECHNOLOGIE/S been receiving favorable news coverage? News headlines about DBVT stock have trended somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. DBV TECHNOLOGIE/S earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news stories about the company an impact score of 45.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for DBV TECHNOLOGIE/S. Who are DBV TECHNOLOGIE/S's major shareholders? DBV TECHNOLOGIE/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.30%), Jennison Associates LLC (2.99%), FMR LLC (2.29%), Boxer Capital LLC (1.87%), Citadel Advisors LLC (0.83%) and VHCP Management II LLC (0.81%). Which institutional investors are selling DBV TECHNOLOGIE/S stock? DBVT stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Bank of America Corp DE, Oak Ridge Investments LLC, FMR LLC, Alps Advisors Inc., Alps Advisors Inc., Alps Advisors Inc. and Daiwa Securities Group Inc.. Which institutional investors are buying DBV TECHNOLOGIE/S stock? DBVT stock was acquired by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Jennison Associates LLC, Janus Henderson Group PLC, Boxer Capital LLC, First Midwest Bank Trust Division, Dynamic Technology Lab Private Ltd and BlackRock Inc.. How do I buy shares of DBV TECHNOLOGIE/S? Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DBV TECHNOLOGIE/S's stock price today? One share of DBVT stock can currently be purchased for approximately $19.22. How big of a company is DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S has a market capitalization of $1.05 billion and generates $13.45 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe. How can I contact DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78. MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 223 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 425MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?